Talazoparib in Combination with Low Dose Radiotherapy (RT) for Lung Cancers

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Lung Cancers+3 More
Talazoparib in Combination with Low Dose Radiotherapy (RT) - Other
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing whether combining talazoparib with low dose consolidative thoracic radiotherapy is safe and what the maximum tolerated dose is. Patients will take talazoparib orally once daily starting on the first day of study intervention until the last day of radiation therapy.

Eligible Conditions
  • Lung Cancers
  • Small Cell Lung Cancer (SCLC)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 5 Secondary · Reporting Duration: Up to 3 years upon enrollment

Year 1
Loco-regional Recurrence
Overall Survival (OS)
Progression-Free Survival (PFS)
Up to 1 year
Acute Toxicities
Chronic Toxicities
Maximum Tolerated Dose (MTD) of Talazoparib in Combination with Low Dose Thoracic Radiotherapy
Year 3
Safety of Talazoparib in Combination with Low Dose Thoracic Radiotherapy

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

Talazoparib in Combination with Low Dose RT
1 of 1
Experimental Treatment

24 Total Participants · 1 Treatment Group

Primary Treatment: Talazoparib in Combination with Low Dose Radiotherapy (RT) · No Placebo Group · Phase 1

Talazoparib in Combination with Low Dose RT
Other
Experimental Group · 1 Intervention: Talazoparib in Combination with Low Dose Radiotherapy (RT) · Intervention Types: Other

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to 3 years upon enrollment

Who is running the clinical trial?

University Health Network, TorontoLead Sponsor
1,368 Previous Clinical Trials
471,829 Total Patients Enrolled
32 Trials studying Lung Cancers
20,846 Patients Enrolled for Lung Cancers
PfizerIndustry Sponsor
4,260 Previous Clinical Trials
7,104,941 Total Patients Enrolled
14 Trials studying Lung Cancers
27,918 Patients Enrolled for Lung Cancers
Benjamin Lok, MDPrincipal InvestigatorPrincess Margaret Cancer Center

Eligibility Criteria

Age 18+ · All Participants · 7 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have completed induction chemotherapy, 4-6 cycles of a platinum agent and etoposide.
You have histological documented diagnosis of lung cancer confirmed by a UHN pathologist.
You are postmenopausal or evidence of non-childbearing status for women of childbearing potential negative urine or serum pregnancy test within 28 days of study treatment and confirmed prior to treatment on day 1.
You have no disease progression (i.e
You have adequate organ and marrow function.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: October 5th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.